Clinical trials: Sickle Cell Crisis
Vaso-occlusive Crisis, Reduction in Hospitalizations
Apixaban in Patients With Sickle Cell Disease
In patients with SCD, the use of low dose anticoagulation as an outpatient may lead to a significant decrease in morbidity and as a result, decrease healthcare utilization and costs.
- Conditions
- Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
- Trial name
- NCT02179177
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Nirmish Shah
Sickle Cell Anemia, Sickle Cell Disease
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).
- Conditions
- Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis
- Trial name
- NCT02433158
- Testing
- Rivipansel
- Where
- 97 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- GlycoMimetics Incorporated
Sickle-Cell Disease with Crisis
Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department
Introduction: This study focuses on the treatment of painful crises in Sickle Cell Disease (SCD) patients using Paracoxib, a non-opioid, compared to Morphine.
- Trial name
- PASC (NCT06315920)
- Testing
- Parecoxib, Morphine
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Oman Medical Speciality Board
Sickle Cell Disease
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
140 SCD patients [70 on Hydroxyurea] will receive Omega-3 capsules whereas another 140 SCD patients [70 on Hydroxyurea] will receive placebo and will be recruited from the Sultan Qaboos University Hospital [SQUH] haematology…
- Trial name
- OM3FA (NCT02525107)
- Testing
- Omega-3 capsules
- Where
- Oman
- Volunteers
- 280 people
- Sponsor
- Sultan Qaboos University
Sickle Cell Disease
Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients
Prospective phase IV interventional open label randomized controlled trial to assess safety and efficacy of glutamine in preventing vaso-occlusive crisis (VOC) episodes in sickle cell pediatrics and adolescents' patients
- Trial name
- Glu_SCD_Egy (NCT05371184)
- Testing
- L-Glutamine, Oral Powder for Reconstitution, Standard of care
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Vaso Occlusive Crisis, Acute Chest Syndrome
Validation of a Predictive Score of Acute Chest Syndrome
Vaso-Occlusive Crisis (VOC), the most common manifestation of sickle cell disease (SCD), is the first cause of death, particularly when complicated by an acute chest syndrome (ACS).
- Trial name
- Presev2 (NCT03032055)
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Soutien aux Actions contre les Maladies du Globule Rouge
Anemia, Sickle Cell
Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
This is a clinical study evaluating the efficacy and safety of rivipansel (GMI-1070) in treating subjects with sickle cell disease (SCD) who are 6 years of age or older experiencing a pain crisis necessitating hospitalization.
- Trial name
- NCT02187003
- Testing
- Rivipansel
- Where
- 142 sites in United States, Canada
- Volunteers
- 345 people
- Sponsor
- Biossil Inc.
Sickle Cell Disease, Vaso-occlusive Crisis
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away in patients with vaso-occlusive crisis (also…
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
- Trial name
- NCT01119833
- Testing
- GMI-1070
- Where
- 22 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- GlycoMimetics Incorporated
Anemia, Sickle Cell
Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis
- Trial name
- NCT02411708
- Testing
- SANGUINATE
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Prolong Pharmaceuticals
Sickle Cell Disease (SCD)
Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging
Background: Painful vasoocclusive crisis (VOC) occurs in people with sickle cell disease (SCD). People with VOC have many visits to the hospital.
- Trial name
- NCT03478917
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)
Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis
The goal of this study is to learn if Ketamine works more efficiently, as compared to Opioids, for Sickle Cell Pain The main questions it aims to answer are: Does Ketamine lower the number of times participants need to be…
- Trial name
- NCT07682662
- Testing
- Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Mississippi Medical Center
Sickle Cell Disease, Vaso-occlusive Crisis
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.
The purpose of this study is to determine the effectiveness of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).
- Trial name
- IMPACTS-2 (NCT01522196)
- Testing
- Varespladib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Anthera Pharmaceuticals
Sickle Cell Disease, Vaso-Occlusive Crisis
Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis
Acute vaso-occlusive episodes (VOEs) in sickle cell disease (SCD) are primarily managed with opioids. Tolerance and hyperalgesia to opioids develops due to N-methyl-D-aspartate (NMDA)-receptor mediated activation of the…
- Trial name
- AKTSS (NCT03296345)
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Anemia, Sickle Cell, Pain
Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis
The purpose of this study is to determine if intranasal fentanyl can decrease the pain of patients with sickle cell disease who present to the pediatric emergency department with a vaso-occlusive crisis.
- Trial name
- NCT01482091
- Testing
- Fentanyl Citrate, Normal Saline
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Montefiore Medical Center
Sickle Cell Disease
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease
- Trial name
- HESTIA3 (NCT03615924)
- Testing
- Ticagrelor
- Where
- 55 sites in United States, Belgium and 14 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca
Sickle Cell Disease
Implication of the Oxydative Stress in the Pathophysiology of Sickle Cell Anemia:
Despite important advances in the current understanding of sickle cell vaso-occlusion, the basis of its control and prevention remain partially unknown.
- Trial name
- STRESS (NCT03368924)
- Testing
- SCA patients (SS genotype)
- Where
- Guadeloupe
- Volunteers
- 38 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Sickle Cell Disease, Pain Crisis Recurrent
Effectiveness of Laying-on-of-hands for Sickle Cell Disease
The objective of this study is to evaluate the effectiveness of 1-year administration of laying-on-of-hands on the morbidity and mortality of patients with sickle cell disease in Africa.
- Conditions
- Sickle Cell Disease, Pain Crisis Recurrent, Anemia, Infection
- Trial name
- NCT01518218
- Testing
- laying-on-of-hands
- Where
- Democratic Republic of the Congo
- Volunteers
- 40 people
- Sponsor
- MOA Health Science Foundation
Sickle Cell Disease, Vaso-occlusive Crisis
Nitrous Oxide Analgesia Vaso-occlusive Crisis
Patients who have sickle cell VOC are usually treated with opioids, such as morphine. However, this current way of treating them has not improved the health, medical outcomes, or rates of hospitalizations.
- Trial name
- NCT01891812
- Testing
- Nitrous oxide 50%
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
Sickle Cell, Sickle Cell Disease
Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients
Sickle cell disease is a chronic disease characterized by multiple vaso-occlusive complications. The basic treatment for patients with a vaso-occlusive crisis (VOC) is based on adequate hydration, oxygen therapy and pain control.
- Conditions
- Sickle Cell, Sickle Cell Disease, Vaso-Occlusive Crises
- Trial name
- ALRCVO-MP (NCT07001189)
- Where
- Guadeloupe
- Volunteers
- 34 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Anemia, Sickle Cell, Anemia; Sickle-Cell, With Crisis
Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell Crisis
This study will investigate the safety, tolerability and potential for the use of up to three daily doses of 30-40 mg/kg HU (daily) upon hospitalization for painful vaso-occlusive crises .
- Trial name
- HELPS (NCT03062501)
- Testing
- Hydroxyurea
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti